Document Detail


Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
MedLine Citation:
PMID:  11722415     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The 'primary' form of chronic cold agglutinin disease is a clonal B-cell lymphoproliferative disorder that is notoriously difficult to treat with drugs, including corticosteroids, alkylating agents, alpha-interferon and purine analogues. We performed a small, open, uncontrolled, prospective study to evaluate the effect of therapy with the monoclonal anti-CD20 antibody rituximab. Six patients with clonal CD20(+)kappa(+) B-cell proliferation received seven courses of rituximab 375 mg/m(2), d 1, 8, 15, and 22. One patient achieved a complete response. Four partial responses were observed, including a response to re-treatment in one patient. Two patients were categorized as non-responders. Haemoglobin levels increased by a median of 4.1 g/dl in the total group and 4.7 g/dl in the responders, who also experienced a substantial improvement of clinical symptoms. The treatment was well tolerated. We discuss the effect of rituximab therapy compared with other treatment options, and try to explain why two individual patients did not respond. Despite the small numbers, the results are very encouraging. Further studies of rituximab therapy for chronic cold agglutinin disease are warranted.
Authors:
S Berentsen; G E Tjønnfjord; R Brudevold; B T Gjertsen; R Langholm; E Løkkevik; J H Sørbø; E Ulvestad
Related Documents :
20431945 - Long-term efficacy and safety of interferon-alpha-2b in patients with mumps orchitis.
6180675 - Treatment of lymphoid neoplasias with interferon. i. human fibroblastic beta-interferon...
12699845 - Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-the...
9131395 - Pilot study of a short course of ribavirin and alpha interferon in the treatment of chr...
19384225 - Duodenal versus gastric feeding in medical intensive care unit patients: a prospective,...
20235065 - A comparison of clinical results of hip resurfacing arthroplasty and 28 mm metal on met...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  115     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-11-27     Completed Date:  2001-12-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  79-83     Citation Subset:  IM    
Affiliation:
Department of Medicine, Haugesund County Hospital, Haugesund, Norway. sigbjorn.berentsen@c2i.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anemia, Hemolytic, Autoimmune / blood,  drug therapy*,  immunology
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology*
B-Lymphocytes / immunology
Bone Marrow Cells / immunology
Chronic Disease
Female
Hemoglobins / metabolism
Humans
Immunoglobulin M / blood
Male
Middle Aged
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Hemoglobins; 0/Immunoglobulin M; 0/rituximab
Comments/Corrections
Comment In:
Br J Haematol. 2002 Jun;117(4):998-9   [PMID:  12060148 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hb H hydrops foetalis syndrome: a case report and review of literature.
Next Document:  The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status.